Recent studies have defined an appropriate CAB LA dosing interval and offered insight into
its safety profile. Phase 3 studies will provide much-anticipated efficacy data. If efficacious …

Introduction: Knowledge of HIV status relies on accurate HIV testing, and is the first step
towards access to HIV treatment and prevention programmes. Globally, HIV-status …

The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last
published in January 2017. The mutations listed are those that have been identified by …

Background Transmitted human immunodeficiency virus (HIV) drug resistance can threaten
the efficacy of antiretroviral therapy and pre-exposure prophylaxis (PrEP). Drug-resistance …

Background Long-acting injectable cabotegravir pre-exposure prophylaxis (PrEP) is
recommended by WHO as an additional option for HIV prevention in sub-Saharan Africa, but …

When used appropriately, pre-exposure prophylaxis (PrEP) substantially reduces the risk of
HIV acquisition. Early implementation outcomes often suggest poor PrEP adherence and …

Abstract Purpose of Review Cabotegravir is a potent integrase strand transfer inhibitor
(INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB …

Objective: HIV remains a significant burden, despite expanding HIV prevention tools. Long-
acting injectable cabotegravir (CAB-LA) is a new preexposure prophylaxis (PrEP) product …

Abstract Background Since January 2017, the recommended first-line antiretroviral regimen
in Brazil is the fixed-dose combination of tenofovir plus lamivudine with dolutegravir (TL+ D) …

Antiretroviral inhibitors that are used to manage HIV infection/AIDS predominantly target
three enzymes required for virus replication: reverse transcriptase, protease, and integrase …